1. Home
  2. PHIN vs HCM Comparison

PHIN vs HCM Comparison

Compare PHIN & HCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo PHINIA Inc.

PHIN

PHINIA Inc.

HOLD

Current Price

$68.52

Market Cap

2.0B

Sector

N/A

ML Signal

HOLD

Logo HUTCHMED (China) Limited

HCM

HUTCHMED (China) Limited

HOLD

Current Price

$15.08

Market Cap

2.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PHIN
HCM
Founded
2023
2000
Country
United States
Hong Kong
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.0B
2.4B
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
PHIN
HCM
Price
$68.52
$15.08
Analyst Decision
Buy
Sell
Analyst Count
5
1
Target Price
$60.80
$13.75
AVG Volume (30 Days)
441.8K
46.4K
Earning Date
02-12-2026
08-07-2025
Dividend Yield
1.56%
N/A
EPS Growth
N/A
N/A
EPS
2.18
0.53
Revenue
$3,427,000,000.00
$602,197,000.00
Revenue This Year
$3.03
N/A
Revenue Next Year
$1.40
$15.54
P/E Ratio
$31.78
$5.46
Revenue Growth
N/A
N/A
52 Week Low
$36.25
$11.51
52 Week High
$70.03
$19.50

Technical Indicators

Market Signals
Indicator
PHIN
HCM
Relative Strength Index (RSI) 75.56 67.64
Support Level $64.74 $14.63
Resistance Level $70.03 $15.26
Average True Range (ATR) 1.61 0.40
MACD 0.36 0.22
Stochastic Oscillator 83.84 94.37

Price Performance

Historical Comparison
PHIN
HCM

About PHIN PHINIA Inc.

Phinia Inc is engaged in the development, design, and manufacture of integrated components and systems that optimize performance, increase efficiency, and reduce emissions in combustion and hybrid propulsion for commercial vehicles, industrial applications, and light vehicles. Its product portfolio includes alternative fuel systems, fuel delivery modules, evaporative canisters, diesel fuel injection systems, electrical systems, hydrogen solutions, associated software, and others. The company's reportable segments are; the Fuel Systems segment, which derives key revenue, and the Aftermarket segment. Geographically, the company generates maximum revenue from the United States and the rest from the United Kingdom, China, Poland, Romania, Brazil, and other regions.

About HCM HUTCHMED (China) Limited

HUTCHMED (China) Ltd is an biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. The company operates in two reportable segments Oncology/Immunology, and Other Ventures.

Share on Social Networks: